### **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

#### FORM 8-K

#### **CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF** THE SECURITIES EXCHANGE ACT OF 1934

June 28, 2017

Date of Report (Date of Earliest Event Reported)

# The Chemours Company (Exact Name of Registrant as Specified in Its Charter)

Delaware (State or Other Jurisdiction Of Incorporation)

001-36794 (Commission File Number)

46-4845564 (I.R.S. Employer Identification No.)

1007 Market Street Wilmington, Delaware, 19899 (Address of principal executive offices)

Registrant's telephone number, including area code: (302) 773-1000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:								
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)							
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)							
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))							
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))							
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).								
	Emerging growth company							
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.								
		_						

#### Item 7.01 Regulation FD Disclosure.

On June 28, 2017, The Chemours Company (the "Company") posted presentation slides to the Investor Relations section of the Company's website which will be used for upcoming discussions with investors and includes an update to previously announced fiscal year 2017 outlook. The presentation slides are furnished herewith as Exhibit 99.1.

The information contained herein and in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended.

#### Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1 Investor Presentation Slides

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THE CHEMOURS COMPANY

**By:** /s/ Mark E. Newman

Mark E. Newman Senior Vice President and Chief Financial Officer

Date: June 28, 2017



# **The Chemours Company**

Investor Deck June 28-29, 2017

#### Safe Harbor Statement and Other Matters

This presentation contains forward-looking statements, within the meaning of the federal securities laws, that involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. The words "believe," "expect," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date the statements were made. These forward-looking statements address, among other things, our agreement with DuPont relating to the MDL Settlement, resolution of environmental liabilities, litigation and other contingencies, Fayetteville site uncertainty, anticipated future operating and financial performance, business plans and prospects, transformation plans, cost savings targets, plans to increase profitability and our outlook for Adjusted EBITDA, free cash flow and target net leverage that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements are based on certain assumptions and expectations of future events which may not be accurate or realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond Chemours' control. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include other risks, uncertainties and other factors discussed in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2016. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.

This presentation contains certain supplemental measures of performance that are not required by, or presented in accordance with, generally accepted accounting principles in the United States ("GAAP"). These Non-GAAP measures include Adjusted Net Income (Loss), Adjusted EPS, Adjusted EBITDA and Free Cash Flow, which should not be considered as replacements of GAAP. Free Cash Flow is defined as Cash from Operations minus cash used for PP&E purchases. Further information with respect to and reconciliations of such measures to the nearest GAAP measure can be found in the appendix hereto.

Management uses Adjusted Net Income (Loss), Adjusted EPS, Adjusted EBITDA and Free Cash Flow to evaluate the Company's performance excluding the impact of certain non-cash charges and other special items in order to have comparable financial results to analyze changes in our underlying business from quarter to quarter.

Additional information for investors is available on the company's website at investors.chemours.com.



.

### The Chemours Company at a Glance



\$5,540 Adj. EBITDA1: \$979 18% % margin:

#### Titanium Technologies

\$2,490 Adj. EBITDA1: 23% % margin:

- Titanium dioxide (TiO<sub>2</sub>) is a pigment used to deliver whiteness, opacity, brightness and protection from sunlight
- #1 global producer of TiO<sub>2</sub> by capacity, sales and profitability

#### Fluoroproducts

Sales1: \$2,385 Adj. EBITDA1: 515 22% % margin:


- Products for high performance applications across broad array of industries, including refrigerants, propellants and industrial resins
- · #1 global producer of both fluorochemicals and fluoropolymers

#### Chemical Solutions


\$665 Sales1: Adj. EBITDA1: % margin: 6%

- · Chemicals used in gold production, oil refining, agriculture, industrial polymers and other industries
- #1 producer in Americas of solid sodium cyanide

#### By Geography(2)



#### By Product(2)





Dollars in millions 5%

© Data represents last twelve months ending March 31, 2017

© Geographic and product data reflect full year 2016 net sales


Adjusted EBITDA includes corporate and other charges which are not reflected in individual segment Adjusted EBITDA. See reconciliation of Adjusted EBITDA in Appendix.


### **Titanium Technologies Business Overview**

#### **Business Overview**

- Global leader in TiO<sub>2</sub> with production capacity of 1.25 million metric tons
  - 4 TiO<sub>2</sub> plants with 7 production lines
  - Packaging facility at Kallo, Belgium
  - Mineral sands mine at Starke, FL
- Industry-leading manufacturing cost position
  - Unique chloride technology
  - Feedstock flexibility
- Strong brand reputation
  - Ti-Pure™ sold to more than 800 customers globally

#### Chemours is #1 in TiO2 Globally(1)







- Coatings architectural, industrial, automotive
- Plastics rigid / flexible packaging, PVC pipe/windows
- Papers laminate papers, coated paper/paperboard, sheet



### Dynamics of the TiO<sub>2</sub> Market



Chemours actions and accomplishments are consistent with our assessment of the opportunities within TiO<sub>2</sub> application segments





### 2017 Pricing Actions

- March 1 price increases announced in February
  - Price increases varied by region, ranging from \$100-€200 per tonne
- July 1 price increases announced in June
  - Price increases ranged from \$130-\$350 per tonne
- Continued differential pricing actions support value provided by Ti-Pure™




Chemours applies a customer value approach to pricing, consistent with factors such as quality, reliability, consistency, business capability, brand



### **Customer Value Proposition**

# Ti-Pure™ total offering and product design provide differential performance and enhanced value to the end user






Chemours Source: SEC filings (10-K, 8-K), Earnings Calls, Slides, TZMI TaiBaiFen 2016 & Chemours estimates


### Fluoroproducts Business Overview

#### **Business Overview**

- Supplies products for high performance applications across broad array of industries
- #1 in Fluoroproducts globally
  - Fluorochemicals: #1 in refrigerants, #1 in propellants, #3 in foaming agents
  - Fluoropolymers: #1 in industrial resins, #1 in fluoropolymer specialties
- Key Brands include Teflon<sup>™</sup>, Freon<sup>™</sup>, Opteon<sup>™</sup>, Krytox™, Nafion™, Viton™

#### Chemours is #1 in Fluoroproducts Globally(2)





Source: Company filings and data, Fluoroproducts: Company filings and Management estimates (1)Reflects full year 2016 segment net sales (2)Fluorochemicals and fluoropolymers market share statistics based on 2015 internal revenue estimates and company filings (3)Includes 100% contribution from the DuPont-Mitsui Fluorocarbon Company joint venture

hemours

- Fluorochemicals mainly refrigerants, propellants, and foam expansion agents
- Fluoropolymers mainly industrial resins and downstream products & coatings
- Key End Markets AC, refrigeration, automotive, aerospace, consumer, wire & cable, electronics and telecommunications

### Fluoropolymers Diverse and Broad End Use Applications



#### **Market Dynamics & Opportunities**

- Strong collaborations in key end markets
- Improved demand across all regions is allowing for positive pricing actions
- Chemours innovations Nafion™
  2050, Teflon™ 30LX, and
  Teflon™ Profile met with great
  enthusiasm
- Regulatory pressures in China potentially causing some producers to limit production
  - Competitive intensity from traditional suppliers

Chemours provides tailored solutions for complex and demanding applications



### Opteon™ Growth

#### Waves of Opteon™ Adoption

#### Mobile Air Conditioning



- More than half of new US vehicles and 100% of EU vehicles have transitioned to HFO technology by end of 2016
  - Expect 50 million cars to be using HFO technology globally by the end of 2017

#### Commercial Stationary Refrigeration



10,000+ supermarkets expected to be using an HFO-blended refrigerant by end of 2020

#### **Foaming Agents**




- Expect to be a larger part of
  Opteon™ portfolio in future due to
  delisting/phase down of legacy
  foaming agents
  - New product launch expected in second half of 2017

#### Residential Stationary Refrigeration




Expect to be a larger part of Opteon™ portfolio in future

#### **Market Dynamics and Opportunities**







Regulatory volume reductions for base refrigerants, partially offset by higher prices

Excess capacity within base business

#### Fluorochemical Revenue Mix






### **Chemical Solutions Overview**

#### **Business Overview**

- Portfolio of industrial businesses primarily operating in the Americas
- Unmatched reputation for safety, reliability and stewardship
- Three production facilities located in North America

#### **Mining Solutions Competitive Advantages**

- Market leadership in the Americas
- Favorable end market dynamics
- Selective, high-return investment opportunity




- Mining Solutions sodium cyanide, hydrogen cyanide, potassium cyanide
- Performance Chemicals and Intermediates –methylamines, glycolic acid, Vazo™ products



### Mining Solutions Supports Gold Production Market in the Americas

#### **Americas Solid Sodium Cyanide Market**



#### Market Size NaCN - Americas/Gold Price



Source: St. Louis Federal Reserve Bank, Import/Export Data, and Internal Estimates

#### The Chemours Advantage

- Aligned with customer values
- On-purpose producer, reliable supply
- Differentiating product stewardship
- Strong logistics network
- Long-term contracts

#### Demand

- NaCN is a critical enabler for gold production
- Gold prices will continue to be volatile but Americas gold production is favored with lower production costs than rest of world
- Remains net import market
- Deteriorating ore quality contributes to NaCN demand growth

Americas NaCN demand forecast to grow at 9% CAGR over the next five years



### **Strong 2017 Financial Performance Expectations**

### 2017 Adjusted EBITDA Expected To Be Above \$1.25 Billion With Positive Free Cash Flow\*

#### **Key Factors Influencing Market Performance**

#### **Market Factors**

- TiO<sub>2</sub> price
- Currency
- End-market demand
- Seasonality
- Regulatory uncertainty

#### **Chemours Initiatives**

- Cost reductions
- Altamira expansion ramp-up
- Opteon market adoption
- Corpus Christi expansion
- Impacts from divestitures

\*Excluding expected \$335 million payment regarding PFOA litigation See reconciliation of estimated Adjusted EBITDA in Appendix





©2017 The Chemours Company. Chemours™ and the Chemours Logo are trademarks or registered trademarks of The Chemours Company





# GAAP Net (Loss) Income to Adjusted EBITDA and Adjusted Net Income Reconciliations

GAAP Net Income (Loss) to Adjusted Net Income and Adjusted EBITDA Tabular Reconciliations (UNAUDITED)

(\$ in millions except per share and unless otherwise noted)	Three months ended March 31,									Three months ended December 31,				
		20	17			20	16	- 10	2016					
	\$ ar	mounts	Spe	er s hare	\$ amounts		\$ per s hare		\$ amounts		\$ per share			
Net income (loss) attributable to Chemours	S	150	S	0.82	S	51	S	0.28	S	(230)	S	(1.26)		
Non-operating pension and other postretirement employee benefit costs (income)		(8)		(0.04)		(7)		(0.04)		(1)		(0.01)		
Exchange (gains) losses		(5)		(0.03)		6		0.03		20		0.11		
Restructuring charges		12		0.07		17		0.09		11		0.06		
Asset related charges 1		-		-		0.7		70		14		0.08		
(Gain) loss on sale of assets or businesses		(16)		(0.09)		(89)		(0.49)		3		0.02		
Transaction costs <sup>2</sup>		_		_		3		0.02		1		0.01		
Legal and other charges <sup>3</sup>		7		0.04		5		0.03		336		1.84		
Provision for (benefit from) income taxes relating to reconciling items 4		2		0.01		25		0.14		(139)		(0.76)		
Adjusted Net Income	S	142	S	0.77	S	11	S	0.08	S	15	S	0.08		
Net income attributable to noncontrolling interests		1				12				2				
Interest expense, net		51				57				58				
Depreciation and amortization		71				66				72				
All remaining provision for (benefit from) income taxes 4		20				(6)				96				
Adjusted EBITDA	S	285			S	128			S	239				
Weighted average number of commons hares outstanding - Basic	183,	408,309			181,	281,166			182,	125, 428				
Weighted average number of commons hares outstanding - Diluted	189,	419,568			181,	503,140			188,	036, 526				
Earnings per share, basic	S	0.82			S	0.28			S	(1.28)				
Earnings per share, diluted <sup>5</sup>	S	0.79			S	0.28			S	(1.28)				
Adjusted earnings per share, basic	S	0.77			s	0.06			s	0.08				
Adjusted earnings per share, diluted <sup>5</sup>	S	0.75			s	0.06			s	0.08				

<sup>1</sup> The three months ended December 31, 2016 includes \$13 million pre-tax asset impair ment of our corporate headquarters building in Wilnington, Delaw are and other asset write-offs.

<sup>&</sup>lt;sup>2</sup> Diuted earnings (loss) per share is calculated using net income (loss) available to common shareholders divided by diluted weighted-average shares of common shares outstanding during each period, which includes univested restricted shares. Diluted earnings per share considers the impact of potentially dilutive securities except in periods in which there is a loss because the inclusion of the potential common shares would have an antidilutive effect.



<sup>&</sup>lt;sup>2</sup> holudes accounting, legal and bankers transaction fees incurred related to the Company's strategic initiatives, which includes transaction costs incurred in connection with the sales of the C&D and Sulfur businesses.

<sup>&</sup>lt;sup>3</sup> Includes litigation settlements, water treatment accrual related to PFOA, and lease termination charges. The quarter ended December 31, 2016 also includes the \$335 million PFOA MIDL settlement accrual.

<sup>&</sup>lt;sup>4</sup> Total of provision for (benefit from) income taxes reconciles to the amount reported in the Consolidated Statements of Operations for the three months ended March 31, 2017 and 2016, and for the three months ended December 31, 2016.

### **Free Cash Flow Reconciliation**

### GAAP Cash Flow to Free Cash Flow Tabular Reconciliations (UNAUDITED)

(\$ in millions unless otherwise noted)

Cash flows provided by (used for) operating activities <sup>1</sup>
Cash flows used for purchases of property, plant and equipment Free cash flows

	Three m	onths ended		
Marc	h 31,	1000	Dece	ember 31,
 2017		2016		2016
\$ 41	S	36	\$	269
(69)		(89)		(103)
\$ (28)	S	(53)	\$	166

<sup>&</sup>lt;sup>1</sup> Cash flows from operating activities for the three months ended March 31, 2016 include the DuPont prepayments of \$190 million received in the first quarter of 2016, of which \$15 million and \$166 million remain outstanding as of March 31, 2017 and 2016, respectively. Excluding the DuPont prepayment, free cash flows for the three months ended March 31, 2016 would have been negative \$219 million.



# **Segment Net Sales and Adjusted EBITDA (unaudited)**

# SEGMENT NET SALES AND ADJUSTED EBITDA (UNAUDITED)

(\$ in millions unless otherwise noted)

		Three months ended December 31,				
	2017		2	2016		2016
SEGMENT NET SALES						
Titanium Technologies	\$	646	\$	521	\$	623
Fluoroproducts		652		531		569
Chemical Solutions	18 <u> </u>	139	<u> </u>	245	20	130
Total Company	\$	1,437	\$	1,297	\$	1,322
SEGMENT ADJUSTED EBITDA						
Titanium Technologies	\$	159	\$	54	\$	157
Fluoroproducts		155		85		111
Chemical Solutions		12		10		9
Corporate & Other	er-	(41)		(21)	_	(38)
Total Company	\$	285	\$	128	\$	239
SEGMENT ADJUSTED EBITDA MARGIN						
Titanium Technologies		25%		10%		25%
Fluoroproducts		24%		16%		20%
Chemical Solutions		9%		4%		7%
Corporate & Other	172	0%	(** <u>**********************************</u>	0%	82	0%
Total Company	85	20%	8 <u>8</u>	10%	22	18%



## **Segment Net Sales (Unaudited)**

#### SEGMENT NET SALES (UNAUDITED) (dollars in millions)

Titanium Technologies Fluoroproducts Chemical Solutions

TOTAL CHEMOURS

	1Q17		1Q17		YTD 2016		4Q16		3Q16		2Q16		1Q16
S	2,490	S	646	S	2,364	S	623	S	625	S	596	S	521
	2,385		652		2,264		569		591		573		531
_	665		139		772		130		182		214		245
5	5,540	5	1,437	5	5,400	5	1,322	\$	1,398	5	1,383	5	1,297

#### SEGMENT ADJUSTED EBITDA (UNAUDITED)

(dollars in millions)

		Q17	1	Q17		2016		4Q16	;	3Q16	2	Q16	1	Q16
Titanium Technologies	S	571	S	159	S	466	S	157	S	144	S	111	S	54
Fluoroproducts		515		155		445		111		143		105		85
Chemical Solutions		41		12		39		9		9		11		10
Corporate & Other	_	(148)		(41)		(128)		(38)		(28)		(40)		(21)
TOTAL CHEMOURS	\$	979	5	285	5	822	5	239	\$	268	\$	187	\$	128

#### SEGMENT ADJUSTED EBITDA MARGIN (UNAUDITED) (dollars in millions)

	1Q17	1Q17	YTD 2016	4Q16	3Q16	2Q16	1Q16
Titanium Technologies	23%	25%	20%	25%	23%	19%	10%
Fluoroproducts	22%	24%	20%	20%	24%	18%	16%
Chemical Solutions	6%	9%	5%	7%	5%	5%	4%
Corporate & Other	0%	0%	0%	0%	0%	0%	0%
TOTAL CHEMOURS	18%	20%	15%	18%	19%	14%	10%



 $<sup>^{\</sup>star}$  Note summation of individual quarters may not sum to the year-to-date (YTD), last twelve months (LTM) or full year amounts due to rounding.

### **Reconciliation of Outlook**

## 2017 Estimated GAAP Net Income to Estimated Adjusted EBITDA Tabular Reconciliation (UNAUDITED)

(\$ in millions unless otherwise noted)

Estimated Net Income 1	>620
Provision for income taxes 12	~165
Interest expense, net	~215
Depreciation and amortization	~280
Other reconciling items 13	~(30)
Estimated Adjusted EBITDA 1	> \$1,250

<sup>&</sup>lt;sup>1</sup> Our estimates reflect our current visibility and expectations of market factors, such as but not limited to, currency movements, TiO₂ prices and end-market demand. Actual results could differ materially from the current estimates due to market factors and unknown or uncertainty of other factors, such as, an estimate of non-operating pension benefit costs with respect to our foreign pension plans including settlements or curtailments, cost savings actions that may be taken in the future, the impact of currency movements on our results including exchange gains and losses and the related tax effects.



<sup>&</sup>lt;sup>2</sup> Provision for income tax is based on our current estimate of geographic mix of earnings and does not include potential tax effect of future discrete items.

<sup>3</sup> Includes non-operating pension benefit income, exchange gains and losses, gain on sale of assets, restructuring and other charges recognized in the first quarter of 2017.



©2017 The Chemours Company. Chemours™ and the Chemours Logo are trademarks or registered trademarks of The Chemours Company